- Funding Received
- $112.5 Million in 3 Rounds from 1 Investor
- Most Recent Funding
- $105 Million Series D on April 15, 2014
- Seattle, WA
- Adaptive Biotechnologies offers research and diagnostic tools for scientists and clinicians involved in genomic immunology.
- Chad Robins, Christopher Carlson, Harlan Robins
- Health Care, Bio-Pharm, Biotechnology
Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.
Current Team (4)Update
Funding Rounds (3) - $112.5MUpdate
1551 Eastlake Ave E
Seattle, WA 98102